A Randomized, Double Blind, Placebo-controlled Study to Assess the the Preemptive Benefit of Etoricoxib in Patients Receiving Anterior Cruciate Ligament Reconstruction
Phase 4
Completed
- Conditions
- Post-operational Pain
- Interventions
- Drug: Arcoxia(etoricoxib 90 mg/tablet)
- Registration Number
- NCT00554346
- Lead Sponsor
- National Taiwan University Hospital
- Brief Summary
Post surgical pain associated with ligament reconstruction may persist for few days after the surgical procedure. Arcoxia is a new anti-inflammatory and analgesic drug that alleviate pain through oral administration. This study will test the safety and efficacy of Arcoxia in the management of post-operational pain in patients receive the ligament reconstruction surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
- Men and women age ranged from 16~35 who have anterior cruciate ligament injury and/or associated injuries are scheduled for ACL reconstruction surgery.
- Patient agrees to participate into this study and is willing to sign the patient informed consent form.
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Arcoxia(etoricoxib 90 mg/tablet) Etoricoxib 90mg 2 Arcoxia(etoricoxib 90 mg/tablet) placebo
- Primary Outcome Measures
Name Time Method Pain at rest at different timepoint after surgical procedures From baseline(preoperation) to 3 days after
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
National Taiwan University Hospital
🇨🇳Taipei, Taiwan